Novo Nordisk (NVO) stock tumbled more than 20% premarket on news that its next-generation obesity drug CagriSema underperformed expectations in a late-stage trial.
Novo Nordisk (NVO) stock tumbled more than 20% premarket on news that its next-generation obesity drug CagriSema underperformed expectations in a late-stage trial.